The regulation and function of cyclin dependent kinase 6 (CDK6)and cyclin dependent kinase 4 (CDK4)ヽyclin complexes are commonly altered with enhanced kinase activity found in hematopoietic malignancies, breast cancer and melanoma making CDK4 and CDK6 attractive targets for therapeutic interference....
Targeting Cyclin Dependent Kinase 4/6 for Cancer Therapy targeted therapies, immunotherapy, or classical chemotherapy to improve future therapeutic uses of CDK4/6 inhibition in a variety of cancers in clinical ... S Shi - 《Transactions on Cancer》 被引量: 0发表: 2023年 Enhancing immunogenic res...
Hyperactivation of RAF proteins, particularly BRAF and CRAF, drives tumour progression and drug resistance in many types of cancer. Although BRAF is the most studied RAF protein, partially owing to its high mutation incidence in melanoma, the role of CRAF in tumourigenesis and drug resistance is ...
dysregulation of cell cycle through affecting expression or activity of CDKs. However, effective application of these methods in the clinical settings requires recognition of the role of CDKs in the progression of each type of cancer, their partners, their interactions with signaling pathways and the...
Although research on the regulatory mechanism of m6A modification of mRNA has made great progress [23], for some non-coding RNAs, especially circRNAs, the regulatory network of m6A has not been fully elucidated [24]. In this review, we summarize the role of m6A modification in circRNA regulati...
Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of therapy resistance is a hot topic in epigenetics. As one of the most common RNA modifications, N6-methyladenosine (m6A) is involved in various processes of RNA meta
In this review, our focus is less on deciphering TXNIP’s prognostic impact but more on the role of TXNIP within the tumor microenvironment (TME), including both tumor cells and host cells, and its impact on different cancer hallmarks. Led by the literature, we pay particular attention to th...
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer Author links open overlay panelAli Masjedi a b c, Vida Hashemi d, Mohammad Hojjat-Farsangi e f, Ghasem Ghalamfarsa g, Gholamreza Azizi h, Mehdi Yousefi a b, Farhad ...
It is well known that hormone receptor-positive (HR+) advanced breast cancer is primarily treated with CDK4/6 inhibitors combined with endocrine therapy, and in cases with PI3K mutations, the treatment can be further combined with alpelisib. So, how should we decide on second-line treatment?
Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast cancer. In this study, we use murine syngeneic tumor models and in vitro assays to investigate the impact of abemaciclib on T cells, the ...